https://scholars.lib.ntu.edu.tw/handle/123456789/551087
標題: | Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection | 作者: | CHEN-HUA LIU CHUN-JEN LIU TUNG-HUNG SU YU-JEN FANG HUNG-CHIH YANG PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2017 | 出版社: | Oxford University Press | 卷: | 4 | 期: | 1 | 來源出版物: | Open Forum Infectious Diseases | 摘要: | Background. Little is known about the risk of hepatitis B virus (HBV) reactivation in patients receiving interferon (IFN)-free direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV). Methods. Patients who were seropositive for HBV core antibody and who received IFN-free DAAs for HCV were enrolled. Hepatitis B virus reactivation was defined as reappearance of serum HBV deoxyribonucleic acid (DNA) ?100 IU/mL in patients with baseline undetectable viral load, or ?2 log10 IU/mL increase of HBV DNA in patients with baseline detectable viral load. Hepatitis B virus-related alanine aminotransferase (ALT) flare was defined as ALT ?5 times upper limit of normal or ?2 times of the baseline level. Hepatitis B virus-related hepatic decompensation was defined as presence of jaundice, coagulopathy, hepatic encephalopathy, or ascites. Results. Compared with no HBV reactivation in 81 HBV surface antigen (HBsAg)-negative patients, 2 of 12 HBsAg-positive patients had HBV reactivation (0% [confidence interval (95% CI), 0%-4.5%] vs 16.7% [95% CI, 4.7%-44.8%], P = .015). No patients had ALT flare or hepatic decompensation. Baseline HBsAg level at a cutoff value of 500 IU/mL was associated with HBV reactivation in HBsAg-positive patients. There was no HBsAg seroreversion in HBsAg-negative patients. Conclusions. Hepatitis B virus reactivation is limited to HBsAg-positive patients receiving IFN-free DAAs for HCV. Higher baseline HBsAg levels are associated with HBV reactivation. The risk of ALT flares or hepatic decompensation is low in these patients. ? The Authors 2017. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028857012&doi=10.1093%2fOFID%2fOFX028&partnerID=40&md5=ab94f822ff83c6d034b6d949197fb457 https://scholars.lib.ntu.edu.tw/handle/123456789/551087 |
ISSN: | 2328-8957 | DOI: | 10.1093/OFID/OFX028 | SDG/關鍵字: | alanine aminotransferase; antivirus agent; bilirubin; dasabuvir plus ombitasvir plus paritaprevir plus ritonavir; hemoglobin; hepatitis B surface antigen; ledipasvir; peginterferon; ribavirin; sofosbuvir; virus DNA; virus RNA; adult; aged; antiviral therapy; Article; bacterial peritonitis; chronic hepatitis C; cohort analysis; decompensated liver cirrhosis; female; Hepatitis B virus; Hepatitis C virus; Hepatitis C virus genotype 2; Hepatitis C virus subtype 1a; Hepatitis C virus subtype 1b; human; major clinical study; male; priority journal; prospective study; risk assessment; viremia; virus load; virus reactivation |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。